Avastin delays course of ovarian cancer

<p>CHICAGO (Reuters) – Adding <span>cancer drug</span> Avastin to customary <span>chemotherapy</span> doubled a length of time a certain organisation of modernized <span>ovarian cancer</span> patients lived but their illness removing worse, according to formula of a clinical trial.</p>
<p> The investigate concerned 361 <span>women</span> whose <span>cancer</span> had stopped responding to normal platinum-based chemotherapy.</p>
<p> After a median follow-up of 13.5 months, 75 percent of Avastin patients had a regularity of cancer, compared to 91 percent of those who perceived chemotherapy alone.</p>
<p> The median time to illness course or genocide was 6.7 months in a multiple organisation and 3.4 months in a chemotherapy group.</p>
<p> “A lot of drugs have been tested in this situation,” pronounced Dr Eric Pujade-Lauraine,...